Immunome’s (IMNM) Outperform Rating Reiterated at Wedbush

Wedbush restated their outperform rating on shares of Immunome (NASDAQ:IMNM) in a research note published on Monday,RTT News reports. They currently have a $33.00 price target on the stock.

Separately, Piper Sandler decreased their price target on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $27.17.

Immunome Stock Up 5.5 %

Shares of NASDAQ IMNM opened at $9.21 on Monday. Immunome has a 52-week low of $8.39 and a 52-week high of $26.70. The stock’s 50 day moving average price is $10.06 and its two-hundred day moving average price is $11.87. The stock has a market capitalization of $734.75 million, a P/E ratio of -1.14 and a beta of 1.93.

Insider Transactions at Immunome

In other Immunome news, CEO Clay B. Siegall bought 150,000 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were purchased at an average cost of $7.75 per share, for a total transaction of $1,162,500.00. Following the transaction, the chief executive officer now directly owns 669,636 shares in the company, valued at $5,189,679. The trade was a 28.87 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Immunome

A number of institutional investors and hedge funds have recently bought and sold shares of IMNM. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Immunome by 32.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,193 shares of the company’s stock valued at $618,000 after purchasing an additional 14,328 shares during the last quarter. Woodline Partners LP lifted its position in shares of Immunome by 6.1% in the fourth quarter. Woodline Partners LP now owns 980,925 shares of the company’s stock worth $10,417,000 after buying an additional 56,533 shares during the last quarter. Two Sigma Advisers LP acquired a new position in Immunome during the fourth quarter valued at approximately $512,000. Two Sigma Investments LP bought a new stake in Immunome during the fourth quarter valued at about $1,640,000. Finally, Point72 Asset Management L.P. increased its position in Immunome by 46.3% in the 4th quarter. Point72 Asset Management L.P. now owns 688,790 shares of the company’s stock worth $7,315,000 after buying an additional 218,143 shares during the period. Institutional investors own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.